Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.50 |
| ▸ | FBP1 | P09467 | 13/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15651463 | 0.82 | CYP19A1 (0.60) | KMT2AALDH1A1KAT6A | |
| SCHEMBL4814114 | 0.82 | GBA1 (0.52) | KMT2AALDH1A1KAT6AMEN1 | |
| SCHEMBL3368190 | 0.82 | PGR (0.51) | KMT2AALDH1A1KAT6AFBP1 | |
| SCHEMBL31404044 | 0.81 | KMT2A (0.77) | KMT2AALDH1A1KAT6AFBP1MEN1 | |
| SCHEMBL350324 | 0.81 | KMT2A (0.77) | KMT2AALDH1A1KAT6AFBP1MEN1 | |
| SCHEMBL1501830 | 0.80 | ALDH1A1 (0.55) | ALDH1A1 | |
| SCHEMBL24956750 | 0.79 | KMT2A (0.74) | KMT2AALDH1A1KAT6AFBP1MEN1 | |
| SCHEMBL13763465 | 0.79 | KMT2A (0.74) | KMT2AALDH1A1KAT6AFBP1MEN1 | |
| SCHEMBL2624207 | 0.79 | ALDH1A1 (0.63) | KMT2AALDH1A1MEN1 | |
| SCHEMBL4818983 | 0.78 | CA1 (0.59) | KMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1740579-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | Abbott Laboratories (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005095387-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-10-13 | — | — | WO | disclosed |
| US-6117821-A | COMPRISING HERBICIDES AND AGRONOMICALLY ACCEPTABLE CARRIERS; USE THEREOF AS BROAD SPECTRUM HERBICIDES WHICH ARE EFFECTIVE AGAINST BOTH MONOCOT AND DICOT WEED SPECIES IN BOTH PREEMERGENCE AND POSTEMERGENCE APPLICATIONS | ROHM AND HAAS COMPANY (US) | 2000-09-12 | — | — | US | disclosed |
| US-4749407-A | N-propargyl-N-(2-trifluoromethylbenzoyl)-3-substituted benzenesulfonamide and selective herbicide containing the same as an active ingredient | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1988-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | KMT2A 1384/4885ALDH1A1 3901/4885KAT6A 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.